The Future Looks Brighter After 25 Years of Retinal Gene Therapy

Human Gene Therapy

Volumn 28, Issue 11, 2017, Pages 982-987

  Auricchio, Alberto ^a,b   Smith, Alexander J ^c   Ali, Robin R ^c,d  

^a TELETHON INSTITUTE OF GENETICS AND MEDICINE TIGEM   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

AAV; eye; ocular gene therapy trials

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; ADENOVIRUS VECTOR; CILIARY NEUROTROPHIC FACTOR; FIBROBLAST GROWTH FACTOR 2; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LENTIVIRUS VECTOR; RETINAL; RETROVIRUS VECTOR;

CELL ENCAPSULATION; CELL SURVIVAL; CHOROIDEREMIA; COLOR BLINDNESS; COMPARATIVE EFFECTIVENESS; HUMAN; IMMUNE RESPONSE; IN VIVO GENE TRANSFER; LEBER CONGENITAL AMAUROSIS; LEBER HEREDITARY OPTIC NEUROPATHY; NONHUMAN; PHOTORECEPTOR CELL; REPORTER GENE; RETINA CELL; RETINA DYSTROPHY; RETINITIS PIGMENTOSA; RETINOSCHISIS; REVIEW; STARGARDT DISEASE; USHER SYNDROME; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WET MACULAR DEGENERATION; ADENOVIRIDAE; ANIMAL; DISEASE MODEL; GENE THERAPY; GENE TRANSFER; GENE VECTOR; GENETICS; LENTIVIRUS; MOUSE; PATHOLOGY; RETINA; RETINA DEGENERATION; THERAPEUTIC USE; TRENDS;

ADENOVIRIDAE; ANIMALS; DISEASE MODELS, ANIMAL; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LENTIVIRUS; MICE; RETINA; RETINAL DEGENERATION;

EID: 85031696763     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2017.164     Document Type: Review

References (55)

1. Price J, Turner D, Cepko C. Lineage analysis in the vertebrate nervous system by retrovirus-mediated gene transfer. Proc Natl Acad Sci U S A 1987;84: 156-160.
2. Li T, Adamian M, Roof D, et al. In vivo transfer of a reporter gene to the retina mediated by an adenoviral vector. Invest Ophthalmol Vis Sci 1994;35:2543-2549.
3. Jomary C, Piper TA, Dickson G, et al. Adenovirusmediated gene transfer to murine retinal cells in vitro and in vivo. FEBS Lett 1994;347:117-122.
4. Ali RR, Reichel MB, Thrasher AJ, et al. Gene transfer into the mouse retina mediated by an adeno-associated viral vector. Hum Mol Genet 1996;5:591-594.
5. Flannery JG, Zolotukhin S, Vaquero MI, et al. Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc Natl Acad Sci U S A 1997;94:6916-6921.
6. Miyoshi H, Takahashi M, Gage FH, et al. Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc Natl Acad Sci U S A 1997;94:10319-10323.
7. Auricchio A. Pseudotyped AAV vectors for constitutive and regulated gene expression in the eye. Vision Res 2003;43:913-918.
8. Allocca M, Mussolino C, Garcia-Hoyos M, et al. Novel adeno-associated virus serotypes efficiently transduce murine photoreceptors. J Virol 2007;81: 11372-11380.
9. Vandenberghe LH, Bell P, Maguire AM, et al. AAV9 targets cone photoreceptors in the nonhuman primate retina. PLoS One 2013;8:e53463.
10. Klimczak RR, Koerber JT, Dalkara D, et al. A novel adeno-associated viral variant for efficient and selective intravitreal transduction of rat Muller cells. PLoS One 2009;4:e7467.
11. Zinn E, Pacouret S, Khaychuk V, et al. In silico reconstruction of the viral evolutionary lineage yields a potent gene therapy vector. Cell Rep 2015;12:1056-1068.
12. Smith AJ, Bainbridge JW, Ali RR. Gene supplementation therapy for recessive forms of inherited retinal dystrophies. Gene Ther 2012;19:154-161.
13. Ali RR, Sarra GM, Stephens C, et al. Restoration of photoreceptor ultrastructure and function in retinal degeneration slow mice by gene therapy. Nat Genet 2000;25:306-310.
14. Sarra GM, Stephens C, De Alwis M, et al. Gene replacement therapy in the retinal degeneration slow (rds) mouse: the effect on retinal degeneration following partial transduction of the retina. Hum Mol Genet 2001;10:2353-2361.
15. Acland GM, Aguirre GD, Ray J, et al. Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 2001;28:92-95.
16. Chevez-Barrios P, Chintagumpala M, Mieler W, et al. Response of retinoblastoma with vitreous tumor seeding to adenovirus-mediated delivery of thymidine kinase followed by ganciclovir. J Clin Oncol 2005;23:7927-7935.
17. Bainbridge JWB, Smith AJ, Barker SS, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med 2008;358: 2231-2239.
18. Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 2008;358:2240-2248.
19. Hauswirth W, Aleman TS, Kaushal S, et al. Phase I trial of Leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adenoassociated virus gene vector: short-term results. Hum Gene Ther 2008;19:979-990.
20. Cideciyan AV, Jacobson SG, Beltran WA, et al. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci U S A 2013;110:E517-E525.
21. Bainbridge JW, Mehat MS, Sundaram V, et al. Long-term effect of gene therapy on Leber's congenital amaurosis. N Engl J Med 2015;372: 1887-1897.
22. Georgiadis A, Duran Y, Ribeiro J, et al. Development of an optimized AAV2/5 gene therapy vector for Leber congenital amaurosis owing to defects in RPE65. Gene Ther 2016;23:857-862.
23. Russell S, Bennett J, Wellman JA, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, Phase 3 trial. Lancet 2017 Jul 13 [Epub ahead of print]; DOI: 10.1016/S0140-6736(17)31868-8.
24. MacLaren RE, Groppe M, Barnard AR, et al. Retinal gene therapy in patients with choroideremia: initial findings from a Phase 1/2 clinical trial. Lancet 2014;383:1129-1137.
25. Feuer WJ, Schiffman JC, Davis JL, et al. Gene therapy for Leber hereditary optic neuropathy: initial results. Ophthalmology 2016;123:558-570.
26. Binley K, Widdowson PS, Kelleher M, et al. Safety and biodistribution of an equine infectious anemia virus-based gene therapy, RetinoStat®, for agerelated macular degeneration. Hum Gene Ther 2012;23:980-991.
27. Constable IJ, Pierce CM, Lai CM, et al. Phase 2a randomized clinical trial: safety and post hoc analysis of subretinal rAAV.sFLT-1 for wet age-related macular degeneration. EBioMedicine 2016;14: 168-175.
28. Heier JS, Kherani S, Desai S, et al. Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a Phase 1, open-label trial. Lancet 2017; 390:50-61.
29. Ba J, Peng RS, Xu D, et al. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and metaanalysis. Drug Des Devel Ther 2015;9:5397-5405.
30. Campochiaro PA, Lauer AK, Sohn EH, et al. Lentiviral vector Gene transfer of Endostatin/angiostatin for Macular degeneration (GEM) Study. Hum Gene Ther 2017;28:99-111.
31. Dalkara D, Byrne LC, Klimczak RR, et al. In vivodirected evolution of a new adeno-associated virus for therapeutic outer retinal gene delivery from the vitreous. Sci Transl Med 2013;5:189ra76.
32. Ramachandran PS, Lee V, Wei Z, et al. Evaluation of dose and safety of AAV7m8 and AAV8BP2 in the non-human primate retina. Hum Gene Ther 2017;28:154-167.
33. Petrs-Silva H, Dinculescu A, Li Q, et al. Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol Ther 2011;19:293-301.
34. Mowat FM, Gornik KR, Dinculescu A, et al. Tyrosine capsid-mutant AAV vectors for gene delivery to the canine retina from a subretinal or intravitreal approach. Gene Ther 2014;21:96-105.
35. Liang FQ, Dejneka NS, Cohen DR, et al. AAVmediated delivery of ciliary neurotrophic factor prolongs photoreceptor survival in the rhodopsin knockout mouse. Mol Ther 2001;3:241-248.
36. McGee Sanftner LH, Abel H, Hauswirth WW, et al. Glial cell line derived neurotrophic factor delays photoreceptor degeneration in a transgenic rat model of retinitis pigmentosa. Mol Ther 2001;4:622-629.
37. Buch PK, MacLaren RE, Duran Y, et al. In contrast to AAV-mediated Cntf expression, AAV-mediated Gdnf expression enhances gene replacement therapy in rodent models of retinal degeneration. Mol Ther 2006;14:700-709.
38. Schuettauf F, Vorwerk C, Naskar R, et al. Adenoassociated viruses containing bFGF or BDNF are neuroprotective against excitotoxicity. Curr Eye Res 2004;29:379-386.
39. Yao J, Feathers KL, Khanna H, et al. XIAP therapy increases survival of transplanted rod precursors in a degenerating host retina. Invest Ophthalmol Vis Sci 2011;52:1567-1572.
40. Schlichtenbrede FC, MacNeil A, Bainbridge JW, et al. Intraocular gene delivery of ciliary neurotrophic factor results in significant loss of retinal function in normal mice and in the Prph2Rd2/Rd2 model of retinal degeneration. Gene Ther 2003; 10:523-527.
41. Birch DG, Bennett LD, Duncan JL, et al. Long-term follow-up of patients with retinitis pigmentosa receiving intraocular ciliary neurotrophic factor implants. Am J Ophthalmol 2016;170:10-14.
42. Sakami S, Kolesnikov AV, Kefalov VJ, et al. P23H opsin knock-in mice reveal a novel step in retinal rod disc morphogenesis. Hum Mol Genet 2014;23: 1723-1741.
43. Li T, Snyder WK, Olsson JE, et al. Transgenic mice carrying the dominant rhodopsin mutation P347S: evidence for defective vectorial transport of rhodopsin to the outer segments. Proc Natl Acad Sci U S A 1996;93:14176-14181.
44. LaVail MM, Yasumura D, Matthes MT, et al. Ribozyme rescue of photoreceptor cells in P23H transgenic rats: long-termsurvival and late-stage therapy. Proc Natl Acad Sci U S A 2000;97:11488-11493.
45. Millington-Ward S, Chadderton N, O'Reilly M, et al. Suppression and replacement gene therapy for autosomal dominant disease in a murine model of dominant retinitis pigmentosa. Mol Ther 2011; 19:642-649.
46. Botta S, Marrocco E, de Prisco N, et al. Rhodopsin targeted transcriptional silencing by DNA-binding. Elife 2016;5:e12242.
47. Fernandez A, Josa S, Montoliu L. A history of genome editing in mammals. Mamm Genome 2017 Jun 6 [Epub ahead of print]; DOI: 10.1007/s00335-017-9699-2.
48. Latella MC, Di Salvo MT, Cocchiarella F, et al. In vivo editing of the human mutant rhodopsin gene by electroporation of plasmid-based CRISPR/Cas9 in the mouse retina. Mol Ther Nucleic Acids 2016;5:e389.
49. Bi A, Cui J, Ma YP, et al. Ectopic expression of a microbial-type rhodopsin restores visual responses in mice with photoreceptor degeneration. Neuron 2006;50:23-33.
50. Tomita H, Sugano E, Yawo H, et al. Restoration of visual response in aged dystrophic RCS rats using AAV-mediated channelopsin-2 gene transfer. Invest Ophthalmol Vis Sci 2007;48:3821-3826.
51. Cehajic-Kapetanovic J, Eleftheriou C, Allen AE, et al. Restoration of vision with ectopic expression of human rod opsin. Curr Biol 2015;25:2111-2122.
52. Busskamp V, Duebel J, Balya D, et al. Genetic reactivation of cone photoreceptors restores visual responses in retinitis pigmentosa. Science 2010;329:413-417.
53. Sengupta A, Chaffiol A, Mace E, et al. Red-shifted channelrhodopsin stimulation restores light responses in blind mice, macaque retina, and human retina. EMBO Mol Med 2016;8:1248-1264.
54. Hegemann P, Moglich A. Channelrhodopsin engineering and exploration of new optogenetic tools. Nat Methods 2011;8:39-42.
55. Trapani I, Colella P, Sommella A, et al. Effective delivery of large genes to the retina by dual AAV vectors. EMBO Mol Med 2014;6:194-211.